Incyte Corporation appointed Bill Meury as CEO following Hervé Hoppenot’s retirement after 11 years at the helm. Meury brings a track record of successful pharmaceutical leadership and dealmaking, having led companies acquired by Novartis and Bristol Myers Squibb. Hoppenot will remain on the board through year-end to support transition. The leadership change coincides with Incyte’s ongoing efforts to diversify beyond its flagship Jakafi franchise.